Literature DB >> 26472628

Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study.

Peter S Bloomfield, Sudhakar Selvaraj, Vincenzo de Paola, Oliver D Howes, Mattia Veronese, Gaia Rizzo, Alessandra Bertoldo, David R Owen, Michael Ap Bloomfield, Ilaria Bonoldi, Nicola Kalk, Federico Turkheimer, Philip McGuire.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether microglial activity, measured using translocator-protein positron emission tomography (PET) imaging, is increased in unmedicated persons presenting with subclinical symptoms indicating that they are at ultra high risk of psychosis and to determine whether microglial activity is elevated in schizophrenia after controlling for a translocator-specific genetic polymorphism.
METHOD: The authors used the second-generation radioligand [(11)C]PBR28 and PET to image microglial activity in the brains of participants at ultra high risk for psychosis. Participants were recruited from early intervention centers. The authors also imaged a cohort of patients with schizophrenia and matched healthy subjects for comparison. In total, 50 individuals completed the study. At screening, participants were genotyped to account for the rs6971 polymorphism in the gene encoding the 18Kd translocator protein. The main outcome measure was total gray matter [(11)C]PBR28 binding ratio, representing microglial activity.
RESULTS: [(11)C]PBR28 binding ratio in gray matter was elevated in ultra-high-risk participants compared with matched comparison subjects (Cohen's d >1.2) and was positively correlated with symptom severity (r=0.730). Patients with schizophrenia also demonstrated elevated microglial activity relative to matched comparison subjects (Cohen's d >1.7).
CONCLUSIONS: Microglial activity is elevated in patients with schizophrenia and in persons with subclinical symptoms who are at ultra high risk of psychosis and is related to at-risk symptom severity. These findings suggest that neuroinflammation is linked to the risk of psychosis and related disorders, as well as the expression of subclinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26472628      PMCID: PMC4821370          DOI: 10.1176/appi.ajp.2015.14101358

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  53 in total

1.  Endotoxin-induced systemic inflammation activates microglia: [¹¹C]PBR28 positron emission tomography in nonhuman primates.

Authors:  Jonas Hannestad; Jean-Dominique Gallezot; Thomas Schafbauer; Keunpoong Lim; Tracy Kloczynski; Evan D Morris; Richard E Carson; Yu-Shin Ding; Kelly P Cosgrove
Journal:  Neuroimage       Date:  2012-07-06       Impact factor: 6.556

2.  Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.

Authors:  K Radewicz; L J Garey; S M Gentleman; R Reynolds
Journal:  J Neuropathol Exp Neurol       Date:  2000-02       Impact factor: 3.685

3.  Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain.

Authors:  Christina S Hines; Masahiro Fujita; Sami S Zoghbi; Jin Su Kim; Zenaide Quezado; Peter Herscovitch; Ning Miao; Maria D Ferraris Araneta; Cheryl Morse; Victor W Pike; Julia Labovsky; Robert B Innis
Journal:  J Nucl Med       Date:  2012-11-12       Impact factor: 10.057

4.  Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia.

Authors:  E M Meisenzahl; D Rujescu; A Kirner; I Giegling; N Kathmann; G Leinsinger; K Maag; U Hegerl; K Hahn; H J Möller
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

5.  Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Authors:  Norbert Müller; Michael Riedel; Constanze Scheppach; Bernd Brandstätter; Safet Sokullu; Karin Krampe; Markus Ulmschneider; Rolf R Engel; Hans-Jürgen Möller; Markus J Schwarz
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

6.  Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.

Authors:  Imran B Chaudhry; Jaime Hallak; Nusrat Husain; Fareed Minhas; John Stirling; Paul Richardson; Serdar Dursun; Graham Dunn; Bill Deakin
Journal:  J Psychopharmacol       Date:  2012-04-23       Impact factor: 4.153

7.  A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.

Authors:  William C Kreisl; Kimberly J Jenko; Christina S Hines; Chul Hyoung Lyoo; Winston Corona; Cheryl L Morse; Sami S Zoghbi; Thomas Hyde; Joel E Kleinman; Victor W Pike; Francis J McMahon; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2012-09-12       Impact factor: 6.200

Review 8.  At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk.

Authors:  Paolo Fusar-Poli; Andreas Bechdolf; Matthew John Taylor; Ilaria Bonoldi; William T Carpenter; Alison Ruth Yung; Philip McGuire
Journal:  Schizophr Bull       Date:  2012-05-15       Impact factor: 9.306

9.  Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis.

Authors:  P Fusar-Poli; M Byrne; S Badger; L R Valmaggia; P K McGuire
Journal:  Eur Psychiatry       Date:  2012-11-06       Impact factor: 5.361

Review 10.  Microglial responses after ischemic stroke and intracerebral hemorrhage.

Authors:  Roslyn A Taylor; Lauren H Sansing
Journal:  Clin Dev Immunol       Date:  2013-10-10
View more
  178 in total

1.  Is Sleep Health a Potential Pathway to Global Mental Health?

Authors:  Hyong Jin Cho
Journal:  Sleep       Date:  2015-12-01       Impact factor: 5.849

Review 2.  The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health.

Authors:  Christopher A Lowry; David G Smith; Philip H Siebler; Dominic Schmidt; Christopher E Stamper; James E Hassell; Paula S Yamashita; James H Fox; Stefan O Reber; Lisa A Brenner; Andrew J Hoisington; Teodor T Postolache; Kerry A Kinney; Dante Marciani; Mark Hernandez; Sian M J Hemmings; Stefanie Malan-Muller; Kenneth P Wright; Rob Knight; Charles L Raison; Graham A W Rook
Journal:  Curr Environ Health Rep       Date:  2016-09

3.  Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Authors:  Deanna L. Kelly; Haley K. Demyanovich; Katrina M. Rodriguez; Daniela Ciháková; Monica V. Talor; Robert P. McMahon; Charles M. Richardson; Gopal Vyas; Heather A. Adams; Sharon M. August; Alessio Fasano; Nicola G. Cascella; Stephanie M. Feldman; Fang Liu; MacKenzie A. Sayer; Megan M. Powell; Heidi J. Wehring; Robert W. Buchanan; James M. Gold; William T. Carpenter; William W. Eaton
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

Review 4.  Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.

Authors:  Dragos Inta; Undine E Lang; Stefan Borgwardt; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

5.  Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Authors:  K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

Review 6.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 7.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

8.  Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances.

Authors:  Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa
Journal:  Schizophr Res       Date:  2018-02-03       Impact factor: 4.939

9.  TSPO expression and brain structure in the psychosis spectrum.

Authors:  Sina Hafizi; Elisa Guma; Alex Koppel; Tania Da Silva; Michael Kiang; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; M Mallar Chakravarty; Romina Mizrahi
Journal:  Brain Behav Immun       Date:  2018-06-12       Impact factor: 7.217

Review 10.  Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma?

Authors:  Andrea Danese; Stephanie J Lewis
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.